Mayotte's Chikungunya Outbreak Increases 190% in Two Weeks

France's ARS Regional Health Agency continues to report chikungunya fever outbreaks in its Departments located east of Africa and Madagascar.

According to the information bulletin released by the Regional Health Agency on May 2, 2025, there have been 89 recorded cases in the Mayotte Department, a significant increase from 32 cases confirmed just two weeks ago.

Mayotte's outbreak breakdown includes 28 imported cases, 28 indigenous cases, and 33 cases currently under investigation. Additionally, two patients have been hospitalized.

The Regional Health Agency indicates that this health risk to the general population and any international visitors is high, and the outbreak could continue for weeks.

Since chikungunya is a vaccine-preventable disease, health authorities announced last week that adults aged 65 and younger will be included in the vaccination campaign in Mayotte.

A recent study found that a disease-blocking vaccine with 75% efficacy, if administered to 40% of individuals aged 12 years and older over three months, could have prevented approximately 34,200 chikungunya cases and 73 related fatalities.

In addition to chikungunya, Mayotte's cholera transmission are localized to Koungou, M'tsangamouji, and Mamoudzou. Mayotte increased its use of the cholera vaccine DUKORAL in the first quarter of 2025.

As of May 6, 2025, the U.S. CDC has not issued a Travel Health Advisory for visiting Mayotte.